Oscar Gary Bukstein, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Central Nervous System Stimulants | 44 | 2020 | 1148 | 3.120 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 56 | 2020 | 3658 | 2.930 |
Why?
|
Methylphenidate | 26 | 2020 | 473 | 2.360 |
Why?
|
Substance-Related Disorders | 40 | 2020 | 4258 | 2.040 |
Why?
|
Attention Deficit and Disruptive Behavior Disorders | 12 | 2020 | 304 | 2.010 |
Why?
|
Aggression | 13 | 2020 | 753 | 1.160 |
Why?
|
Alcohol-Related Disorders | 10 | 2013 | 234 | 1.090 |
Why?
|
Risperidone | 9 | 2017 | 383 | 0.920 |
Why?
|
Conduct Disorder | 9 | 2014 | 241 | 0.820 |
Why?
|
Alcoholism | 20 | 2018 | 1906 | 0.730 |
Why?
|
Delayed-Action Preparations | 10 | 2020 | 968 | 0.720 |
Why?
|
Psychotropic Drugs | 12 | 2018 | 894 | 0.680 |
Why?
|
Guanfacine | 4 | 2014 | 51 | 0.670 |
Why?
|
Adolescent Behavior | 9 | 2022 | 1151 | 0.640 |
Why?
|
Family Therapy | 3 | 2014 | 207 | 0.620 |
Why?
|
Mass Screening | 3 | 2022 | 5255 | 0.560 |
Why?
|
Evidence-Based Practice | 1 | 2020 | 500 | 0.540 |
Why?
|
Mental Disorders | 18 | 2022 | 6600 | 0.530 |
Why?
|
Adrenergic alpha-2 Receptor Agonists | 2 | 2014 | 87 | 0.520 |
Why?
|
Parent-Child Relations | 2 | 2016 | 747 | 0.490 |
Why?
|
Suicide | 3 | 2022 | 1477 | 0.470 |
Why?
|
Adolescent | 84 | 2022 | 85781 | 0.460 |
Why?
|
School Health Services | 2 | 2013 | 375 | 0.410 |
Why?
|
Health Education | 3 | 2014 | 1056 | 0.410 |
Why?
|
Hydrocortisone | 2 | 2011 | 1826 | 0.410 |
Why?
|
Marijuana Abuse | 3 | 2012 | 403 | 0.400 |
Why?
|
Acetylcysteine | 1 | 2012 | 272 | 0.380 |
Why?
|
Child | 69 | 2022 | 77709 | 0.370 |
Why?
|
Excitatory Amino Acid Antagonists | 1 | 2012 | 449 | 0.360 |
Why?
|
Adrenergic alpha-Agonists | 5 | 2011 | 177 | 0.350 |
Why?
|
Personality | 1 | 2013 | 552 | 0.350 |
Why?
|
Testosterone | 2 | 2011 | 2420 | 0.340 |
Why?
|
Fluoxetine | 8 | 2011 | 749 | 0.340 |
Why?
|
Androstenedione | 1 | 2009 | 131 | 0.330 |
Why?
|
Personality Assessment | 7 | 2008 | 647 | 0.330 |
Why?
|
Parents | 15 | 2017 | 3407 | 0.320 |
Why?
|
Saliva | 2 | 2011 | 809 | 0.320 |
Why?
|
Substance Abuse Detection | 2 | 2008 | 283 | 0.310 |
Why?
|
Comorbidity | 27 | 2019 | 10388 | 0.310 |
Why?
|
Dehydroepiandrosterone | 1 | 2009 | 252 | 0.310 |
Why?
|
Referral and Consultation | 2 | 2020 | 3528 | 0.300 |
Why?
|
Alcohol Drinking | 6 | 2013 | 3966 | 0.290 |
Why?
|
Depressive Disorder, Major | 12 | 2022 | 4644 | 0.280 |
Why?
|
Child Behavior | 1 | 2022 | 839 | 0.280 |
Why?
|
Diagnosis, Dual (Psychiatry) | 8 | 2009 | 295 | 0.270 |
Why?
|
Membrane Lipids | 1 | 2006 | 248 | 0.260 |
Why?
|
Psychiatric Status Rating Scales | 14 | 2020 | 6038 | 0.260 |
Why?
|
Psychiatry | 1 | 2017 | 1695 | 0.250 |
Why?
|
Humans | 131 | 2022 | 744343 | 0.240 |
Why?
|
Depression | 2 | 2022 | 7766 | 0.240 |
Why?
|
Double-Blind Method | 21 | 2020 | 12026 | 0.230 |
Why?
|
Clonidine | 3 | 2009 | 164 | 0.230 |
Why?
|
Basal Ganglia | 1 | 2006 | 546 | 0.230 |
Why?
|
Dose-Response Relationship, Drug | 14 | 2020 | 10943 | 0.220 |
Why?
|
Phospholipids | 1 | 2006 | 784 | 0.220 |
Why?
|
Antidepressive Agents | 5 | 2022 | 2838 | 0.210 |
Why?
|
Antipsychotic Agents | 7 | 2017 | 3057 | 0.210 |
Why?
|
Psychotherapy | 10 | 2022 | 1643 | 0.210 |
Why?
|
Drug Administration Schedule | 8 | 2020 | 4933 | 0.190 |
Why?
|
Male | 83 | 2020 | 350118 | 0.190 |
Why?
|
Practice Guidelines as Topic | 4 | 2018 | 7279 | 0.190 |
Why?
|
Telemedicine | 1 | 2017 | 2872 | 0.180 |
Why?
|
Prefrontal Cortex | 2 | 2008 | 2147 | 0.180 |
Why?
|
Dysthymic Disorder | 2 | 2009 | 74 | 0.180 |
Why?
|
Mood Disorders | 4 | 2020 | 1106 | 0.170 |
Why?
|
Female | 79 | 2020 | 380194 | 0.170 |
Why?
|
Behavior Therapy | 4 | 2010 | 865 | 0.170 |
Why?
|
Drug Therapy, Combination | 12 | 2017 | 6489 | 0.170 |
Why?
|
Temporal Lobe | 1 | 2006 | 1670 | 0.170 |
Why?
|
Diagnostic and Statistical Manual of Mental Disorders | 8 | 2020 | 1953 | 0.170 |
Why?
|
Treatment Outcome | 35 | 2022 | 63114 | 0.160 |
Why?
|
Antidepressive Agents, Second-Generation | 3 | 2010 | 503 | 0.160 |
Why?
|
Bipolar Disorder | 4 | 2014 | 5027 | 0.160 |
Why?
|
Sex Characteristics | 1 | 2009 | 2585 | 0.160 |
Why?
|
Mental Health | 1 | 2022 | 3019 | 0.160 |
Why?
|
Pennsylvania | 9 | 2009 | 613 | 0.150 |
Why?
|
Violence | 2 | 2022 | 909 | 0.150 |
Why?
|
Affective Symptoms | 1 | 2020 | 407 | 0.150 |
Why?
|
Combined Modality Therapy | 15 | 2017 | 8642 | 0.150 |
Why?
|
Age of Onset | 4 | 2014 | 3271 | 0.150 |
Why?
|
Interview, Psychological | 5 | 2011 | 812 | 0.140 |
Why?
|
Phosphorus | 2 | 2008 | 338 | 0.140 |
Why?
|
Analysis of Variance | 5 | 2016 | 6365 | 0.140 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2006 | 3760 | 0.140 |
Why?
|
Child Psychiatry | 2 | 2009 | 220 | 0.130 |
Why?
|
Patient Satisfaction | 3 | 2016 | 3396 | 0.130 |
Why?
|
Anxiety Disorders | 5 | 2020 | 2690 | 0.130 |
Why?
|
Risk Factors | 14 | 2022 | 72290 | 0.130 |
Why?
|
Peer Group | 4 | 2014 | 635 | 0.130 |
Why?
|
Administration, Cutaneous | 4 | 2009 | 711 | 0.120 |
Why?
|
Achievement | 1 | 2016 | 291 | 0.120 |
Why?
|
Dyslexia | 1 | 2017 | 248 | 0.120 |
Why?
|
Data Interpretation, Statistical | 1 | 2004 | 2716 | 0.120 |
Why?
|
Psychometrics | 5 | 2020 | 3002 | 0.120 |
Why?
|
Delivery of Health Care | 1 | 2022 | 5319 | 0.120 |
Why?
|
Forensic Psychiatry | 2 | 2011 | 200 | 0.120 |
Why?
|
Fathers | 1 | 2016 | 358 | 0.120 |
Why?
|
Cross-Over Studies | 7 | 2020 | 2029 | 0.110 |
Why?
|
Personality Development | 2 | 1991 | 245 | 0.110 |
Why?
|
Depressive Disorder | 7 | 2004 | 3748 | 0.110 |
Why?
|
Child Abuse | 2 | 2011 | 1030 | 0.110 |
Why?
|
Reading | 1 | 2017 | 558 | 0.110 |
Why?
|
Patient Acceptance of Health Care | 2 | 2011 | 3022 | 0.110 |
Why?
|
Socialization | 1 | 1993 | 87 | 0.110 |
Why?
|
Social Perception | 1 | 2016 | 425 | 0.110 |
Why?
|
Child Custody | 1 | 2011 | 20 | 0.100 |
Why?
|
Internal-External Control | 1 | 2014 | 363 | 0.100 |
Why?
|
Child of Impaired Parents | 4 | 1992 | 455 | 0.100 |
Why?
|
Suicide, Attempted | 3 | 2009 | 1221 | 0.100 |
Why?
|
Juvenile Delinquency | 1 | 2011 | 125 | 0.100 |
Why?
|
Child Behavior Disorders | 5 | 2008 | 807 | 0.100 |
Why?
|
Severity of Illness Index | 13 | 2020 | 15540 | 0.090 |
Why?
|
Cognition Disorders | 3 | 2012 | 4043 | 0.090 |
Why?
|
Motivation | 3 | 2011 | 1971 | 0.090 |
Why?
|
Urban Population | 1 | 1998 | 2021 | 0.090 |
Why?
|
Adolescent Psychiatry | 2 | 2009 | 148 | 0.090 |
Why?
|
Prevalence | 7 | 2009 | 15226 | 0.090 |
Why?
|
Psychology | 2 | 2009 | 356 | 0.080 |
Why?
|
Expert Testimony | 1 | 2011 | 356 | 0.080 |
Why?
|
Ganglia | 1 | 2008 | 89 | 0.080 |
Why?
|
Hospitals, Psychiatric | 3 | 2002 | 332 | 0.080 |
Why?
|
Parenting | 2 | 2014 | 679 | 0.080 |
Why?
|
Affect | 1 | 2016 | 1476 | 0.080 |
Why?
|
Child Development Disorders, Pervasive | 1 | 2013 | 615 | 0.080 |
Why?
|
Alcohol Deterrents | 2 | 2005 | 39 | 0.080 |
Why?
|
Critical Pathways | 2 | 2001 | 476 | 0.080 |
Why?
|
Treatment Refusal | 1 | 2011 | 421 | 0.080 |
Why?
|
Drug Synergism | 4 | 2016 | 1792 | 0.070 |
Why?
|
Family | 4 | 2009 | 3147 | 0.070 |
Why?
|
Social Behavior | 4 | 2015 | 1127 | 0.070 |
Why?
|
Malpractice | 1 | 2011 | 572 | 0.070 |
Why?
|
Sexuality | 1 | 2008 | 174 | 0.070 |
Why?
|
Ethics, Medical | 1 | 2011 | 792 | 0.070 |
Why?
|
Schools | 2 | 2008 | 1433 | 0.070 |
Why?
|
Bupropion | 1 | 2008 | 303 | 0.070 |
Why?
|
Community Mental Health Services | 1 | 2009 | 386 | 0.070 |
Why?
|
Mothers | 1 | 2016 | 2165 | 0.070 |
Why?
|
Renal Agents | 1 | 2004 | 32 | 0.060 |
Why?
|
Self Report | 1 | 2016 | 3558 | 0.060 |
Why?
|
Alcohol-Induced Disorders | 1 | 2005 | 26 | 0.060 |
Why?
|
Enuresis | 1 | 2004 | 47 | 0.060 |
Why?
|
Deamino Arginine Vasopressin | 1 | 2004 | 91 | 0.060 |
Why?
|
Early Diagnosis | 1 | 2009 | 1184 | 0.060 |
Why?
|
Crisis Intervention | 2 | 2002 | 105 | 0.060 |
Why?
|
Medication Adherence | 2 | 2016 | 2063 | 0.060 |
Why?
|
Adult | 18 | 2017 | 214055 | 0.060 |
Why?
|
Restraint, Physical | 2 | 2002 | 193 | 0.060 |
Why?
|
Emergency Services, Psychiatric | 1 | 2003 | 68 | 0.060 |
Why?
|
Neuropsychological Tests | 2 | 2020 | 6993 | 0.060 |
Why?
|
Personality Inventory | 3 | 2009 | 1030 | 0.060 |
Why?
|
Ambulatory Care Facilities | 1 | 2009 | 933 | 0.050 |
Why?
|
Follow-Up Studies | 12 | 2017 | 39050 | 0.050 |
Why?
|
Cognition | 1 | 2020 | 6770 | 0.050 |
Why?
|
Serotonin Uptake Inhibitors | 1 | 2001 | 33 | 0.050 |
Why?
|
Young Adult | 5 | 2022 | 56430 | 0.050 |
Why?
|
Magnetic Resonance Angiography | 1 | 2008 | 1442 | 0.050 |
Why?
|
Substance Abuse Treatment Centers | 3 | 2004 | 168 | 0.050 |
Why?
|
Sex Factors | 5 | 2008 | 10397 | 0.050 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 3870 | 0.050 |
Why?
|
Program Development | 1 | 2008 | 1316 | 0.050 |
Why?
|
Patient Isolation | 1 | 2001 | 100 | 0.050 |
Why?
|
Reference Values | 2 | 2005 | 4982 | 0.050 |
Why?
|
Drug Delivery Systems | 2 | 2009 | 2219 | 0.050 |
Why?
|
Adaptation, Psychological | 1 | 1991 | 2576 | 0.040 |
Why?
|
Cross-Sectional Studies | 8 | 2008 | 25043 | 0.040 |
Why?
|
Residential Treatment | 1 | 2000 | 111 | 0.040 |
Why?
|
Risk-Taking | 1 | 2005 | 986 | 0.040 |
Why?
|
Placebos | 3 | 2011 | 1676 | 0.040 |
Why?
|
Meta-Analysis as Topic | 1 | 2004 | 1344 | 0.040 |
Why?
|
Evidence-Based Medicine | 3 | 2007 | 3610 | 0.040 |
Why?
|
Electroconvulsive Therapy | 1 | 2004 | 477 | 0.040 |
Why?
|
Demography | 1 | 2004 | 1656 | 0.040 |
Why?
|
Time Factors | 6 | 2017 | 40075 | 0.040 |
Why?
|
Circadian Rhythm | 1 | 2011 | 2624 | 0.040 |
Why?
|
Social Environment | 2 | 2008 | 1023 | 0.040 |
Why?
|
Research | 1 | 2007 | 1999 | 0.040 |
Why?
|
Health Personnel | 1 | 2022 | 3218 | 0.040 |
Why?
|
Alcoholic Intoxication | 3 | 2005 | 188 | 0.040 |
Why?
|
Psychological Techniques | 1 | 2018 | 45 | 0.040 |
Why?
|
Data Collection | 2 | 2004 | 3341 | 0.040 |
Why?
|
Obsessive-Compulsive Disorder | 2 | 1999 | 1444 | 0.040 |
Why?
|
Drug Utilization | 1 | 2003 | 1183 | 0.040 |
Why?
|
Patient Compliance | 3 | 2017 | 2684 | 0.040 |
Why?
|
Synapses | 1 | 2006 | 1728 | 0.040 |
Why?
|
Single-Blind Method | 2 | 2013 | 1590 | 0.040 |
Why?
|
Prognosis | 3 | 2008 | 29063 | 0.040 |
Why?
|
Child, Preschool | 5 | 2022 | 41006 | 0.040 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2008 | 9959 | 0.040 |
Why?
|
Individuality | 2 | 2001 | 307 | 0.030 |
Why?
|
Primary Health Care | 1 | 2022 | 4558 | 0.030 |
Why?
|
United States | 10 | 2018 | 69872 | 0.030 |
Why?
|
Wounds and Injuries | 2 | 2005 | 2400 | 0.030 |
Why?
|
Serotonin | 1 | 2020 | 1017 | 0.030 |
Why?
|
Age Factors | 3 | 2008 | 18370 | 0.030 |
Why?
|
Stress Disorders, Post-Traumatic | 3 | 2010 | 4266 | 0.030 |
Why?
|
Impulsive Behavior | 1 | 2017 | 316 | 0.030 |
Why?
|
Nerve Net | 1 | 2006 | 2174 | 0.030 |
Why?
|
Patient Care Management | 1 | 2018 | 306 | 0.030 |
Why?
|
Electrocardiography | 1 | 2008 | 6442 | 0.030 |
Why?
|
Sleep | 2 | 2008 | 4623 | 0.030 |
Why?
|
Perceptual Distortion | 1 | 1994 | 35 | 0.030 |
Why?
|
Clonazepam | 1 | 1994 | 136 | 0.030 |
Why?
|
Defense Mechanisms | 1 | 1994 | 178 | 0.030 |
Why?
|
Clinical Trials as Topic | 1 | 2009 | 7913 | 0.030 |
Why?
|
Stereotyped Behavior | 1 | 2013 | 136 | 0.030 |
Why?
|
Secondary Prevention | 2 | 2009 | 1530 | 0.030 |
Why?
|
Behavioral Symptoms | 1 | 2014 | 175 | 0.030 |
Why?
|
Social Adjustment | 2 | 1994 | 631 | 0.030 |
Why?
|
Feasibility Studies | 2 | 2014 | 5078 | 0.020 |
Why?
|
Developmental Disabilities | 1 | 2019 | 1456 | 0.020 |
Why?
|
Patient Dropouts | 1 | 1992 | 421 | 0.020 |
Why?
|
Hospitalization | 4 | 1994 | 10262 | 0.020 |
Why?
|
Administration, Oral | 2 | 2010 | 3913 | 0.020 |
Why?
|
Memory, Short-Term | 1 | 2016 | 975 | 0.020 |
Why?
|
Emergency Service, Hospital | 1 | 2009 | 7659 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2005 | 12959 | 0.020 |
Why?
|
Recreation | 1 | 2009 | 115 | 0.020 |
Why?
|
Canada | 1 | 2014 | 2065 | 0.020 |
Why?
|
Life Change Events | 1 | 1993 | 938 | 0.020 |
Why?
|
Temperament | 1 | 1990 | 283 | 0.020 |
Why?
|
Erythema | 1 | 2009 | 257 | 0.020 |
Why?
|
Observer Variation | 2 | 2007 | 2593 | 0.020 |
Why?
|
Control Groups | 1 | 2008 | 105 | 0.020 |
Why?
|
Patient Admission | 1 | 1995 | 1380 | 0.020 |
Why?
|
Case-Control Studies | 4 | 2007 | 21746 | 0.020 |
Why?
|
Learning | 1 | 2017 | 1713 | 0.020 |
Why?
|
Case Management | 1 | 2009 | 286 | 0.020 |
Why?
|
Confidentiality | 1 | 2011 | 612 | 0.020 |
Why?
|
Neurons | 1 | 2006 | 9338 | 0.020 |
Why?
|
Behavior, Addictive | 1 | 1993 | 462 | 0.020 |
Why?
|
Propylamines | 1 | 2007 | 165 | 0.020 |
Why?
|
Self Efficacy | 1 | 2011 | 616 | 0.020 |
Why?
|
Self Concept | 1 | 1993 | 1025 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 1 | 2008 | 17446 | 0.020 |
Why?
|
Incidence | 3 | 1995 | 20947 | 0.020 |
Why?
|
Firearms | 1 | 1993 | 598 | 0.020 |
Why?
|
Osmosis | 1 | 2006 | 113 | 0.020 |
Why?
|
Bradycardia | 1 | 2008 | 307 | 0.020 |
Why?
|
Prodrugs | 1 | 2007 | 268 | 0.020 |
Why?
|
Anorexia | 1 | 2006 | 161 | 0.020 |
Why?
|
Personality Disorders | 1 | 1990 | 713 | 0.020 |
Why?
|
Tachycardia | 1 | 2008 | 619 | 0.020 |
Why?
|
Interpersonal Relations | 1 | 1993 | 1425 | 0.020 |
Why?
|
Educational Status | 2 | 2008 | 2540 | 0.020 |
Why?
|
Physician's Role | 1 | 2011 | 943 | 0.020 |
Why?
|
Family Health | 1 | 2009 | 1282 | 0.020 |
Why?
|
Education | 1 | 2007 | 543 | 0.020 |
Why?
|
Epidemiologic Methods | 1 | 2009 | 1364 | 0.010 |
Why?
|
Patient Education as Topic | 1 | 2014 | 2278 | 0.010 |
Why?
|
Sleep Stages | 1 | 2008 | 686 | 0.010 |
Why?
|
Drug Tolerance | 1 | 2005 | 376 | 0.010 |
Why?
|
Drug Resistance | 1 | 2009 | 1609 | 0.010 |
Why?
|
Pilot Projects | 2 | 2008 | 8324 | 0.010 |
Why?
|
Long QT Syndrome | 1 | 2008 | 453 | 0.010 |
Why?
|
Personal Satisfaction | 1 | 2008 | 643 | 0.010 |
Why?
|
Drug Interactions | 1 | 2008 | 1460 | 0.010 |
Why?
|
Matched-Pair Analysis | 1 | 2003 | 288 | 0.010 |
Why?
|
Brazil | 1 | 2007 | 1270 | 0.010 |
Why?
|
Recurrence | 2 | 2005 | 8340 | 0.010 |
Why?
|
Pemoline | 1 | 2002 | 18 | 0.010 |
Why?
|
Drug Evaluation | 1 | 2004 | 647 | 0.010 |
Why?
|
Functional Laterality | 1 | 2008 | 2290 | 0.010 |
Why?
|
Health Status | 1 | 1995 | 4034 | 0.010 |
Why?
|
Hospitals, University | 1 | 2003 | 571 | 0.010 |
Why?
|
Benzhydryl Compounds | 1 | 2007 | 845 | 0.010 |
Why?
|
Regression Analysis | 2 | 2001 | 6459 | 0.010 |
Why?
|
Prospective Studies | 3 | 2010 | 53288 | 0.010 |
Why?
|
Amphetamines | 1 | 2002 | 148 | 0.010 |
Why?
|
Tics | 1 | 2001 | 70 | 0.010 |
Why?
|
Social Support | 1 | 2011 | 2118 | 0.010 |
Why?
|
Psychopharmacology | 1 | 2002 | 143 | 0.010 |
Why?
|
Counseling | 1 | 2008 | 1523 | 0.010 |
Why?
|
Child Day Care Centers | 1 | 2000 | 123 | 0.010 |
Why?
|
Appetite | 1 | 2001 | 243 | 0.010 |
Why?
|
Patient Advocacy | 1 | 2001 | 353 | 0.010 |
Why?
|
Narcolepsy | 1 | 2002 | 195 | 0.010 |
Why?
|
Linear Models | 1 | 2009 | 5952 | 0.010 |
Why?
|
Program Evaluation | 1 | 2008 | 2488 | 0.010 |
Why?
|
Social Isolation | 1 | 2002 | 365 | 0.010 |
Why?
|
Emergencies | 1 | 2005 | 1170 | 0.010 |
Why?
|
Headache | 1 | 2006 | 1226 | 0.010 |
Why?
|
Acute Disease | 1 | 2009 | 7149 | 0.010 |
Why?
|
Algorithms | 2 | 2009 | 13881 | 0.010 |
Why?
|
Models, Psychological | 1 | 2002 | 811 | 0.010 |
Why?
|
Students | 1 | 2008 | 1654 | 0.010 |
Why?
|
Antihypertensive Agents | 1 | 2007 | 2046 | 0.010 |
Why?
|
Psychotic Disorders | 2 | 2007 | 3046 | 0.010 |
Why?
|
North America | 1 | 2001 | 1249 | 0.010 |
Why?
|
Interviews as Topic | 1 | 2004 | 2539 | 0.010 |
Why?
|
Quality of Life | 2 | 2009 | 12804 | 0.010 |
Why?
|
Sleep Initiation and Maintenance Disorders | 1 | 2006 | 1004 | 0.010 |
Why?
|
History, 20th Century | 1 | 2004 | 2740 | 0.010 |
Why?
|
Heart Rate | 1 | 2008 | 4091 | 0.010 |
Why?
|
Logistic Models | 2 | 2003 | 13408 | 0.010 |
Why?
|
South Australia | 1 | 1995 | 19 | 0.010 |
Why?
|
Drug Monitoring | 1 | 2002 | 956 | 0.010 |
Why?
|
Brain | 1 | 2002 | 26385 | 0.010 |
Why?
|
Thioridazine | 1 | 1994 | 33 | 0.010 |
Why?
|
Weight Loss | 1 | 2006 | 2622 | 0.010 |
Why?
|
Clomipramine | 1 | 1994 | 54 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 1991 | 13989 | 0.010 |
Why?
|
Chronic Disease | 1 | 2009 | 9146 | 0.010 |
Why?
|
Diazepam | 1 | 1994 | 205 | 0.010 |
Why?
|
Utilization Review | 1 | 1995 | 392 | 0.010 |
Why?
|
Liver Function Tests | 1 | 1995 | 528 | 0.010 |
Why?
|
Phobic Disorders | 1 | 1995 | 439 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 1997 | 3508 | 0.010 |
Why?
|
Cluster Analysis | 1 | 1997 | 2715 | 0.010 |
Why?
|
Adjustment Disorders | 1 | 1990 | 70 | 0.010 |
Why?
|
Culture | 1 | 1993 | 633 | 0.010 |
Why?
|
Survival Analysis | 1 | 2001 | 10252 | 0.000 |
Why?
|
Odds Ratio | 1 | 1997 | 9849 | 0.000 |
Why?
|
Retrospective Studies | 1 | 1992 | 77449 | 0.000 |
Why?
|
Health Behavior | 1 | 1995 | 2636 | 0.000 |
Why?
|
Borderline Personality Disorder | 1 | 1990 | 736 | 0.000 |
Why?
|
Reproducibility of Results | 1 | 2000 | 19905 | 0.000 |
Why?
|
Patient Readmission | 1 | 1995 | 3114 | 0.000 |
Why?
|
Length of Stay | 1 | 1992 | 6309 | 0.000 |
Why?
|
Smoking | 1 | 1995 | 8987 | 0.000 |
Why?
|